Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE

CONCORDE is the first phase I drug-radiotherapy (RT) combination platform in non–small-cell lung cancer, designed to assess multiple different DNA damage response inhibitors in combination with radical thoracic RT. Time-to-event continuous reassessment method (TiTE-CRM) methodology will inform dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, Katrina, Hinsley, Samantha, Phillip, Rachel, Oughton, Jamie B., Murden, Geraldine, Chalmers, Anthony J., Faivre-Finn, Corinne, Greystoke, Alastair, Brown, Sarah R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812638/
https://www.ncbi.nlm.nih.gov/pubmed/36446040
http://dx.doi.org/10.1200/PO.22.00133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812638/
https://www.ncbi.nlm.nih.gov/pubmed/36446040
http://dx.doi.org/10.1200/PO.22.00133

Ejemplares similares